Table 1.
Final diagnosis and distribution of patients in three subgroups.
| Groups | N (%) of patients | Age at onset (median) | Female/male | No. (%) of immunosuppressive therapya |
|---|---|---|---|---|
| (NMOSD)-ON−TM− | 70 (100) | 30 | 60/10 | 7 (10) |
| NMO* | 38 (54.3) | 30 | 35/3 | 3 (7.9) |
| RLETM | 8 (11.4) | 39 | 7/1 | 1 (12.5) |
| APTM | 3 (4.3) | 28 | 2/1 | 0 |
| MON | 3 (4.3) | 30 | 3/0 | 0 |
| RON | 2 (2.9) | 28.43 | 1/1 | 0 |
| Othersb | 16 (22.9) | 26 | 12/4 | 3 (18.8%) |
| NMOSD-ON+ | 95 (100) | 37 | 83/12 | 22 (23.2%) |
| NMO* | 78 (82.1) | 38 | 69/9 | 20 (25.6%) |
| RON | 12 (12.6) | 37 | 9/3 | 2 (16.7%) |
| MON | 5 (5.3) | 25 | 5/0 | 0 |
| NMOSD-TM+ | 116 (100) | 40 | 98/18 | 10 (8.6) |
| NMO* | 51 (44.00) | 42 | 44/7 | 5 (9.8) |
| RLETM | 40 (34.5) | 40 | 34/6 | 5 (12.5) |
| MLETM | 22 (19.0) | 43 | 17/5 | 0 |
| APTM | 3 (2.6) | 36 | 3/0 | 0 (0) |
| NMO | 11 (100) | 49 | 11/0 | 2 (6.8) |
NMOSD, neuromyelitis optica spectrum disorder; NMO, neuromyelitis optica; RLETM, recurrent longitudinal extensive transverse myelitis; MLETM, monophasic LETM; APTM, acute partial transverse myelitis; RON, recurrent optic neuritis; MON, monophasic ON.
aLong therapy with azathioprine, cyclophosphamide, methotrexate, and mycophenolate mofetil.
bPatients without optic neuritis (ON) and transverse myelitis (TM).
*Significantly different among the three groups (p < 0.0001).